Verastem is a clinical-stage biopharmaceutical company engaged in discovering and developing drugs to treat cancer through targeted killing of cancer stem cells, which are an underlying cause of tumor recurrence and metastasis. The company is developing FAK, PI3K/mTOR and Wnt, which are small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation. For more information, visit the company’s Web site at www.verastem.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: